Areas of Interest

Oncology

Andrew Hass
hass_andrew@lilly.com
Search & Evaluation – Oncology
Lilly Research Labs

Nathan Hubbard
hubbard_nathan_e@lilly.com
Transactions – Oncology & Diagnostics
Corporate Business Development


At Lilly Oncology, we are looking for breakthrough monotherapy programs as well as opportunities for rational combinations with our existing pipeline.


Our greatest oncology interests lie in novel assets in the following oncology areas:

  • Novel immunotherapy approaches — T-cell redirection and novel checkpoint agents
  • Agents targeting the tumor microenvironment and interplay between the microenvironment and immune system
  • Tumor metabolism pathway modulators
  • Epigenetic modulators

We have an emphasis on the following oncology indications:

  • Lung cancer - NSCLC and SCLC
  • GI cancer — colorectal, gastric, and hepatocellular cancers
  • Breast malignancies

Neuroscience

Ryan Westphal, Ph.D.
westphal_ryan@lilly.com
Search & Evaluation – Neuroscience
Lilly Research Labs

Jennifer Laird, Ph.D.
laird_jennifer@lilly.com
Search & Evaluation – Neuroscience
Lilly Research Labs

Michael Andrew Johnson
johnson_michael_andrew@lilly.com
Transactions – BioMedicines &Manufacturing
Corporate Business Development


Our greatest interests lie in the following areas:

Neurodegenerative diseases

  • Novel therapeutic approaches for disease modification in neurodegenerative diseases, especially Alzheimer’s Disease and Parkinson’s Disease
  • Novel treatments that address the symptoms of neurodegenerative disease including psychosis, cognitive impairment, agitation, mood and sleep

Pain and Migraine

  • Novel approaches to treat chronic neuropathic, inflammatory and visceral pain
  • Migraine prophylaxis

Neuropsychiatric Symptoms of Disease

  • Late stage opportunities to mood disorders with novel mechanisms
  • Psychosis and agitation associated with indications such as Alzheimer’s disease and Parkinson’s disease

Other areas of consideration

  • Novel, transformative therapeutic approaches for additional diseases including: Epilepsy, Bipolar Disorders, Depression, Schizophrenia, ADHD, Autism, PTSD, and Anxiety

Diabetes

Brian Bloomquist, Ph.D.
bloomquist_brian_t@lilly.com
Search & Evaluation – Diabetes
Lilly Research Labs

Travis Coy
coy_travis_a@lilly.com
Transactions – Diabetes & Devices
Corporate Business Development


Our greatest interests lie in the following areas:

  • Next-generation prandial or basal insulins (especially ultra-rapid, long-acting, high-concentration, or glucose-responsive, but also novel combinations, thermostable, or oral)
  • Oral GLP-1/dual-acting GLP-1 mimetics
  • Next-generation glucagons (soluble and/or emergency)
  • Novel insulin sensitizers
  • Beta cell health (increased regeneration/proliferation/transdifferentiation; reduced apoptosis)
  • Modulation of white adipose to brown adipose tissue conversion
  • Pathways relating to lipotoxicity
  • Diabetic kidney disease/nephropathy
  • NASH
  • Novel approaches relevant to the development of an artificial pancreas
  • Novel insulin secretagogues
  • Breakthrough diabetes device technology
  • Reduction of hepatic glucose output
  • Other endocrine disorders (e.g., growth disorders and major unmet medical needs)

Note: Highest priority for molecules is given to those validated as ‘Glucose-Plus’ agents (e.g., drugs that reduce HbA1c and elicit weight loss and/or improvements in other CV risk factors, etc.); interest includes both small and large molecules, and Type 2 and Type 1 diabetes

Immunology

Heather Wasserman, Ph.D.
wasserman_heather_a@lilly.com
Search & Evaluation – Immunology
Lilly Research Labs

Michael Andrew Johnson
johnson_michael_andrew@lilly.com
Transactions – Diabetes & Devices
Corporate Business Development


The immunology platform’s mission is to address unmet medical needs with best-in-disease or best-in-class medicines and to deliver unparalleled customer experiences—with a strong focus on small molecule and biologics in the following indications:

  • Rheumatoid arthritis
  • Psoriasis
  • System lupus erythematosus
  • Crohn’s disease
  • Ulcerative colitis

Lilly Immunology is also interested in the following indications:

  • Ankylosing spondylitis
  • Psoriatic arthritis
  • Lupus nephritis

Biotechnology Discovery Research

Brian Edmonds, Ph.D.
edmonds_brian_t@lilly.com
Search & Evaluation – New Technology
Corporate Business Development

Vanessah Ng
ng_vanessah_k@lilly.com
Transactions – Lilly Research Labs
Corporate Business Development


Our greatest interests lie in the following areas:

  • Protein expression / production technologies
    • Non-mammalian / microbial expression and production systems
    • Cell culture
    • Antibody / Fab production systems
    • Early identification of high expressing cell lines
    • Purification processes
    • Glycosylation
    • Formulation design
  • Protein Optimization / Engineering
    • Bi-specific / multi-functional platforms
    • mA b / alternative scaffolds
    • Half-life extension of antibodies, peptides and proteins
      • Alternatives to PEG-ylation
    • Site-specific chemical modification
  • Antibody Drug Conjugates: novel linker, conjugation chemistries and warheads
  • Peptide chemistry: semi-synthetic, recombinant and conjugation chemistries
  • Protein: protein interactions
  • Assessment of biodistribution
  • Drug delivery
    • Oral
    • Blood Brain Barrier
    • Invivo delivery of nucleic acids(shRNA, miRNA, antisense, mRNA

Emerging Markets

Gurkeerat Singh, Ph.D.
singh_gurkeerat@lilly.com
Search & Evaluation – Emerging Markets
Lilly Research Labs

Michael Andriole
andriole_michael_t@lilly.com
Transactions – Emerging Markets & Project Management
Corporate Business Development


Our greatest interests lie in the following areas:

In-Licensing and Co-Development

Oncology

  • Thoracic Cancer & Breast Cancer
  • Gastrointestinal: Gastric, Colorectal, Hepatocellular Carcinoma, Pancreatic Cancer
  • Immuno-oncology

Neuroscience

  • Neurodegenerative Disorders: Approaches that affect disease progression or modification and/or address major symptoms of the disease
  • Pain and Migraine

Diabetes

  • Novel oral anti-diabetic agents
  • Ultra rapid-acting insulins

Out-Licensing

  • Regional/local development of select Lilly pipeline molecules

Strategic Partnerships

  • Geographic Commercial Partnerships, Local Manufacturing Partnerships, Public-Private Partnerships

Drug Delivery and Devices

Veena Rao
rao_veena@lilly.com
Search & Evaluation – Drug Delivery and Devices
Lilly Research Labs

Travis Coy
coy_travis_a@lilly.com
Transactions – Diabetes & Devices
Corporate Business Development


Our greatest interests lie in the following areas:

Advances in auto-injector pens and wearable injector platforms, including:

  • Wireless remote medication monitoring including apps
  • High-volume applications
  • High-viscosity applications

Advances in “patch pump” delivery technology, including:

  • Subcutaneous delivery
  • Wireless remote control and monitoring
  • Patient-intuitive applications

Oral peptide delivery technology

Advances in Artificial Pancreas Device Systems (APDS)

  • Advanced polymer materials for container/closure applications
  • Closed-loop systems (sensors, delivery devices and software algorithms) to improve health outcomes

New technology to deliver therapeutic agents:

  • To the central nervous system across the blood-brain barrier
  • Via needle free technologies
  • Transdermal patches
  • Time-action modulation (small and large molecules)
  • Preservation technology to enable multi-use biological preps

High-dose biological delivery

  • Formulation technology to reduce viscosity of biologics in solution
  • Device technology to deliver high-volume (>2ml) and/or high viscosity (>10 cpd) biologic solutions

Delivery of multi-pharmacology (enabling technologies including devices)

  • Fixed-dose combinations (small and large molecule)
  • Bi-specific or combined dose antibodies

Other Areas

  • Real-time monitoring of diseases via sensors and cameras — for diabetes, Alzheimer’s, immunology and potentially oncology
  • Medical algorithms for use in software apps

Regional Innovation

Johnston Erwin
erwin_m_johnston_jr@lilly.com
Search & Evaluation
Corporate Business Development

Tim Luker
luker_timothy@lilly.com
Search & Evaluation
Corporate Business Development

Ronit Phail
phail_ronit_r@lilly.com
Search & Evaluation
Corporate Business Development

Vanessah Ng
ng_vanessah_k@lilly.com
Transactions – Lilly Research Labs
Corporate Business Development


As part of Lilly's overall Research and Development strategy, we focus on "hot spots" of innovation. Regional collaborations link outstanding science with the expertise of Lilly scientists across a broad range of therapeutic areas to form the next generation of breakthrough biopharmaceutical companies. We offer access to our industry experts, including Lilly's Chorus* team, whom provide insights on a number of additional areas: regulatory, commercial, reimbursement, CM&C, etc.


  • New York City — The City of New York is home to a number of premier life science Universities and has the highest number of publications of any metropolitan area in the U.S. Lilly’s New York City Research and Development site works to discover and advance a diverse Oncology pipeline. Lilly is a limited partner in both the City of New York Early-Stage Life Sciences Fund and the Accelerator IV Fund.
  • United Kingdom — The U.K. has a high concentration of world-class research institutions and the highest rate of new biotech start-ups outside the U.S. Lilly’s Erl Wood Research & Development site near London focuses on neuroscience research and development of Lilly’s pipeline across several therapeutic areas. We have built on these links with a network of virtual innovation offices in biotech centers across the U.K. Lilly is a limited partner in the Epidarex Capital II Fund.
  • Seattle — The growing scientific community of Seattle has a number of proven leaders in discovery and development of new and innovative medicines. Washington consistently ranks near the top five states by deal number and top ten states for investment dollars. Although Lilly does not have a physical presence in Seattle, Lilly actively participates in shaping medicines across a variety of therapeutic areas. Lilly is a limited partner in the Accelerator IV fund.

*Chrorus is the early phase virtual drug development team within Lilly. It is a full-service R&D unit within Lilly that specializes in drug development from candidate selection to clinical proof-of-concept. Chorus quickly achieves proof-of-concept at a low cost while positioning successful projects for “pharma quality” late-stage development.

Cardiovascular

Chris Vlahos, Ph.D.
vlahos_chris_j@lilly.com
Search & Evaluation – Cardiovascular
Lilly Research Labs

Michael Andrew Johnson
johnson_michael_andrew@lilly.com
Transactions – BioMedicines & Manufacturing
Corporate Business Development


Our greatest interests lie in the following areas:

Cardiovascular In Scope:

  • LDL-C Reduction for Patients with Severe Hypercholesterolemia
  • CV Event Reduction in Patients/Mixed Dyslipidemia (HDL-C)
  • Chronic Heart Failure (CHF)
  • Resistant Hypertension
  • Acute Heart Failure
  • Event Reduction through Plaque Stabilization
  • Stroke Prophylaxis in Atrial Fibrillation

Cardiovascular Out of Scope (unless Phase 3):

  • Stable Angina (no option patient)
  • Acute Stroke
  • Ventricular Arrhythmias (adjunct to device)
  • Acute MI/Myocardial Protection
  • Abdominal Aortic Aneurysm (AAA)
  • Peripheral Arterial Disease (PAD) (small vessel disease)

Chorus

Hsiao D. Lieu, M.D.
lieu_hsiao_d@lilly.com
Chorus
Lilly Research Labs


Chorus is a fully-integrated Lilly R&D unit with the ability to be a strategic development partner for external programs.


  • Full-service, autonomous R&D unit within Lilly
  • Specializes in drug development from candidate selection to clinical proof-of-concept (PoC)
  • Focuses only on those experiments that can provide quick go/no go decisions and create strong PoC data packages
  • Pulls risk forward and increases marketability of the development program by implementing development work that drives the largest change in technical probability of success and greatest value in the shortest time

The Chorus lean-and-efficient model improves productivity in both time and cost compared to average pharmaceutical R&D metrics. Since its creation in 2002, Chorus has completed more than 50 internal Lilly and external-sponsored programs in various clinical indications in 19 countries.